To evaluate the twice daily oral administration of mogroside, in combination with ribavirin for the treatment of genotype-1, treatment-naive hepatitis-C patients

Trial Profile

To evaluate the twice daily oral administration of mogroside, in combination with ribavirin for the treatment of genotype-1, treatment-naive hepatitis-C patients

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2014

At a glance

  • Drugs Mogroside IV (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Compassionate
  • Most Recent Events

    • 13 Aug 2014 New trial record
    • 01 Jul 2014 Topline results published in a Canopus BioPharma Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top